At a Glance
- Company: Bristol Myers Squibb
- Partner: Anthropic
- Focus area: Generative AI for drug development
- Goal: Unlock insights from internal data silos
- Next steps: Deploy Claude tools across R&D workflows
What happened?
Bristol Myers Squibb has partnered with Anthropic to bring its Claude AI tools into the drugmaker’s research and development workflow. The collaboration is aimed at using generative AI to help speed up drug discovery and development.
Why does it matter?
Pharma companies sit on large amounts of data that are often scattered across separate systems, making it difficult to extract useful insights quickly. A partnership like this could help Bristol Myers analyse those data more efficiently and identify patterns that might otherwise be missed.
Who’s behind it?
Bristol Myers Squibb is one of the world’s largest biopharmaceutical companies, with a broad oncology, immunology and cardiovascular portfolio. Anthropic is an AI company best known for its Claude large language models.
How was it achieved?
The collaboration centres on integrating Claude into Bristol Myers Squibb’s internal processes, with the aim of improving how teams query, summarise and work with complex scientific and operational data. In practice, that could support everything from literature review to target selection and trial planning.
What’s next?
The next phase is likely to focus on implementation across R&D teams and testing where AI adds the most value. If successful, the deal could become a model for how large pharma uses generative AI beyond basic productivity tasks and into core drug development work.